Skip to main content

Mind Medicine Mindmed Inc(MNMD-Q)
NASDAQ

Today's Change
Real-Time Last Update Last Sale Cboe BZX Real-Time

MindMed Reports Third Quarter 2022 Financial Results and Business Highlights

Newswire.ca - Thu Nov 10, 2022

– Initiated Phase 2b dose-optimization trial in patients with Generalized Anxiety Disorder, with first patients dosed in Q3 2022 and key clinical readout expected in late 2023 –

Read more at newswire.ca

Provided Content: Content provided by Newswire.ca. The Globe and Mail was not involved, and material was not reviewed prior to publication.

More from The Globe